A phase I study (NCT06496568) is currently exploring the feasibility of monotherapy for advanced solid tumors with PIK3CA mutations, including recurrent/metastatic HNSCC. The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.